Altimmune's Q2 Loss Widens Slightly Amid Headquarters Relocation To New Jersey

Altimmune Inc. (ALT), a late clinical-stage biopharmaceutical company, on Wednesday announced financial results for the second quarter, noting a mild increase in loss owing to increased operating expenses.